Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Michael P. Agius, Laura Hevenor, N Connor Payne, Qi Liu, Hyuk-Soo Seo, Romanos Sklavenitis-Pistofidis, Daniel Heilpern-Mallory, Puspalata Bashyal, Michelle P. Aranha, Elizabeth D. Lightbody, Ralph Mazitschek, Sirano Dhe-Paganon, Jun Qi, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 155.

https://doi.org/10.1182/blood-2024-203381

Published: 2024

Journal Articles

Targeting Proline Trna Biogenesis for Treatment of T Cell Acute

Valerio Ciaurro, Priyanshu Srivastava, Abdul Khalique, Jared Brottem, N Connor Payne, Ralph Mazitschek, Palaniraja Thandapani

Blood (2024) 144 (Supplement 1): 5835.

https://doi.org/10.1182/blood-2024-200359

Published: 2024

Journal Articles

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

Mike P. Agius, Laura Hevenor, N Connor Payne, Ralph Mazitschek, Hyuk-Soo Seo, Sirano Dhe-Paganon, Jun Qi, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2023-186864

Published: 2023

Journal Articles

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 890.

https://doi.org/10.1182/blood-2021-148536

Published: 2021

Journal Articles

Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function

Matthew Ho, Jiye Liu, PhD, Alireza Kalbasi, PharmD, Takeshi Harada, MDPhD, Teru Hideshima, MD PhD, Paul Dowling, BSc, PhD, Yu-Tzu Tai, PhD, Li Zhang, MD, Kenneth Wen, BS, Ralph Mazitschek, Amanda McCann, Kenneth C Anderson, MD, Peter O'Gorman, MD PhD FRCP, FRCPath, Giada Bianchi, MD

Blood (2017) 130 (Supplement 1): 4429.

https://doi.org/10.1182/blood.V130.Suppl_1.4429.4429

Published: 2017

Journal Articles

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Takeshi Harada, MD PhD, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Shohei Kikuchi, MD PhD, Morihiko Sagawa, MD PhD, Yu-Tzu Tai, PhD, Ralph Mazitschek, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4472.

https://doi.org/10.1182/blood.V128.22.4472.4472

Published: 2016

Journal Articles

Induction of Human Fetal Hemoglobin Expression by Selective Inhibitors of Histone Deacetylase 1 and 2 (HDAC1/2)

Jeffrey R Shearstone, PhD, John H van Duzer, PhD, James E Bradner, MD, Ralph Mazitschek, PhD, Simon S Jones, Matthew Jarpe, PhD

Blood (2012) 120 (21): 3259.

https://doi.org/10.1182/blood.V120.21.3259.3259

Published: 2012

Journal Articles

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung, Jen-Chieh Tseng, David Tamang, Min Yang, Matthew Jarpe, John H. van Duzer, Ralph Mazitschek, Walter C. Ogier, Diana Cirstea, Scott Rodig, Homare Eda, Tyler Scullen, Miriam Canavese, James Bradner, Kenneth C. Anderson, Simon S. Jones, Noopur Raje

Blood (2012) 119 (11): 2579–2589.

https://doi.org/10.1182/blood-2011-10-387365

Published: 2012

Includes: Supplemental data

Journal Articles

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Diana Cirstea, MD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Scott Rodig, MD, PhD, Miriam Canavese, PhD, James Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2908.

https://doi.org/10.1182/blood.V118.21.2908.2908

Published: 2011

Journal Articles

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Walter C Ogier, Diana D. Cirstea, MD, Scott Rodig, MD, PhD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Miriam Canavese, PhD, James E. Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2912.

https://doi.org/10.1182/blood.V118.21.2912.2912

Published: 2011

Journal Articles

Tubacin, An Inhibitor of HDAC6, Induces Apoptosis of Acute Lymphoblastic Leukemia Cells in Vitro and in Vivo through a Na+/K+ATPase-Dependent Pathway.

Agustin Rodriguez-Gonzalez, Ph.D., Tiffany Simms-Waldrip, M.D., Alan K. Ikeda, M.D., Tara Lin, M.D., Brett Lomenick, Grace Aldana-Masangkay, Ralph Mazitschek, Ph.D., James Bradner, Cecilia Fu, M.D., Kathleen M. Sakamoto, M.D., Ph.D.

Blood (2008) 112 (11): 1923.

https://doi.org/10.1182/blood.V112.11.1923.1923

Published: 2008

Journal Articles

Targeting Histone Deacetylase 6 and the Aggresome Pathway in Acute Lymphoblastic Leukemia Cells.

Augustin Rodriguez-Gonzalez, PhD, James Ch’ng, Alan K. Ikeda, M.D., Tara Lin, M.D., Bita Bahrami, Ralph Mazitschek, Ph.D., James E. Bradner, M.D., Cecilia Fu, M.D., Kathleen M. Sakamoto, M.D., Ph.D.

Blood (2007) 110 (11): 1602.

https://doi.org/10.1182/blood.V110.11.1602.1602

Published: 2007

Journal Articles

A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

James Bradner, MD, Edward Greenberg, B.S., Sridevi Ponduru, M.D., Vishal Patel, B.S., Stuart Schreiber, Ph.D., Benjamin Rich, Ph.D., Ralph Mazitschek, Ph.D.

Blood (2007) 110 (11): 800.

https://doi.org/10.1182/blood.V110.11.800.800

Published: 2007

Journal Articles

Histone deacetylase inhibitors increase virus gene expression but decrease CD8 + cell antiviral function in HTLV-1 infection

Angelina Jane Mosley, Kiran N. Meekings, Corinna McCarthy, Dawn Shepherd, Vincenzo Cerundolo, Ralph Mazitschek, Yuetsu Tanaka, Graham P. Taylor, Charles R. Bangham

Blood (2006) 108 (12): 3801–3807.

https://doi.org/10.1182/blood-2006-03-013235

Published: 2006

Includes: Supplemental data

Journal Articles

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, James E. Bradner, MD, Hiroshi Yasui, MD, PhD, Noopur Raje, MD, Dharminder Chauhan, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Constantine Mitsiades, MD, PhD, Paul G. Richardson, MD, Ralph Mazitschek, PhD, Stuart L. Schreiber, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3426.

https://doi.org/10.1182/blood.V108.11.3426.3426

Published: 2006

Journal Articles

Design and Characterization of a Novel, Reverse Prodrug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

James E. Bradner, MD, Edward F. Greenberg, BS, Stuart L. Schreiber, PhD, Ralph Mazitschek, PhD

Blood (2006) 108 (11): 4759.

https://doi.org/10.1182/blood.V108.11.4759.4759

Published: 2006

NARROW

Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Targeting Proline Trna Biogenesis for Treatment of T Cell Acute

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Induction of Human Fetal Hemoglobin Expression by Selective Inhibitors of Histone Deacetylase 1 and 2 (HDAC1/2)

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Tubacin, An Inhibitor of HDAC6, Induces Apoptosis of Acute Lymphoblastic Leukemia Cells in Vitro and in Vivo through a Na+/K+ATPase-Dependent Pathway.

Targeting Histone Deacetylase 6 and the Aggresome Pathway in Acute Lymphoblastic Leukemia Cells.

A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

Histone deacetylase inhibitors increase virus gene expression but decrease CD8 + cell antiviral function in HTLV-1 infection

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

Design and Characterization of a Novel, Reverse Prodrug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only